Search

Your search keyword '"Sakai, Hisamune"' showing total 136 results
Start Over Author "Sakai, Hisamune"
136 results on '"Sakai, Hisamune"'

7. Immunophenotypes and Tumor Immune Microenvironment in Hepatocellular Carcinoma With Macrotrabecular Massive and Vessels Encapsulating Tumor Clusters

Author

AKIBA, JUN, primary, NAKAYAMA, MASAMICHI, additional, KONDO, REIICHIRO, additional, KUSANO, HIRONORI, additional, OGASAWARA, SACHIKO, additional, MIHARA, YUTARO, additional, TANIGAWA, MASAHIKO, additional, TSUTSUI, KANA, additional, YANO, YUTA, additional, MIYAZAKI, DAIKI, additional, TOKISAWA, SAEKO, additional, MITSUHASHI, TOSHIYUKI, additional, NOMURA, HIDETOSHI, additional, SANADA, SAKIKO, additional, SAKAI, HISAMUNE, additional, HISAKA, TORU, additional, and YANO, HIROHISA, additional

Published
2024
Full Text
View/download PDF

11. Haemoglobin, albumin, lymphocyte, and platelet (HALP) score is a useful predictor of prognosis after hepatectomy for hepatocellular carcinoma: a retrospective, propensity score matching cohort study

Author

Hashimoto, Kazuaki, primary, Kanno, Hiroki, additional, Sakai, Hisamune, additional, Miyazaki, Daiki, additional, Fukutomi, Shogo, additional, Arai, Shoichiro, additional, Goto, Yuichi, additional, Akashi, Masanori, additional, Isobe, Taro, additional, Mori, Naoki, additional, Ishibashi, Nobuya, additional, Fujita, Fumihiko, additional, and Hisaka, Toru, additional

Published
2023
Full Text
View/download PDF

12. Significance of Desmoplastic Histopathological Growth Pattern for Colorectal Liver Metastases Treated With Preoperative Chemotherapy

Author

HIRAKAWA, HIROAKI, primary, SAKAI, HISAMUNE, additional, KANNO, HIROKI, additional, GOTO, YUICHI, additional, AKASHI, MASANORI, additional, FUKUTOMI, SHOGO, additional, ARAI, SHOICHIRO, additional, SATO, TOSHIHIRO, additional, SUDO, TOMOYA, additional, NAGASU, SACHIKO, additional, MIWA, KEISUKE, additional, NAITO, YOSHIKI, additional, AKIBA, JUN, additional, YANO, HIROHISA, additional, FUJITA, FUMIHIKO, additional, and HISAKA, TORU, additional

Published
2023
Full Text
View/download PDF

15. Impact of Interferon on the Prognosis of Hepatitis C Virus-Related Hepatocellular Carcinoma Patients with a Sustained Virological Response –An Additional Comparison Between Preoperative and Postoperative Sustained Virological Response–

Author

MUROYA, DAISUKE, primary, NISHIMURA, TARO, additional, KANNO, HIROKI, additional, KOJIMA, SATOKI, additional, FUKUTOMI, SHOGO, additional, AKASHI, MASANORI, additional, NOMURA, YORIKO, additional, GOTO, YUICHI, additional, SATO, TOSHIHIRO, additional, SAKAI, HISAMUNE, additional, HISAKA, TORU, additional, AKAGI, YOSHITO, additional, and OKUDA, KOJI, additional

Published
2023
Full Text
View/download PDF

18. Salvage PTBD With Chemotherapy Improves Survival in Patients With Unresectable Malignant Biliary Obstruction – A Single Center Retrospective Study

Author

MUROYA, DAISUKE, primary, TSURU, HIROTOSHI, additional, SHIMOKOBE, HISAAKI, additional, NAGAO, YUICHI, additional, YOSHIMOTO, YASUNORI, additional, WADA, YOSHITO, additional, HAYASHI, KOUJI, additional, TANIWAKI, SATOSHI, additional, MIDORIKAWA, RYUTA, additional, TANIWAKI, SHINICHI, additional, KOJIMA, SATOKI, additional, ARAI, SHOICHIRO, additional, SHIRAHAMA, TAKAHISA, additional, GOTO, YUICHI, additional, SAKAI, HISAMUNE, additional, YOSHITOMI, MUNEHIRO, additional, HISAKA, TORU, additional, AKAGI, YOSHITO, additional, and OKUDA, KOJI, additional

Published
2022
Full Text
View/download PDF

21. Predictive and Prognostic Value of SUOX Expression in Pancreatic Ductal Adenocarcinoma

Author

NAITO, YOSHIKI, primary, AKIBA, JUN, additional, KINJO, YOSHINAO, additional, SADASHIMA, EIJI, additional, OGATA, TOSHIRO, additional, YANO, YUTA, additional, TANIGAWA, MASAHIKO, additional, NAKAYAMA, MASAMICHI, additional, KAWAHARA, AKIHIKO, additional, OKABE, YOSHINOBU, additional, SAKAI, HISAMUNE, additional, HISAKA, TORU, additional, AKAGI, YOSHITO, additional, and YANO, HIROHISA, additional

Published
2022
Full Text
View/download PDF

22. Assessing the incidence of complications and malignancies in the long-term management of benign biliary strictures with a percutaneous transhepatic drain

Author

Yoshitomi, Munehiro, primary, Kawahara, Ryuichi, additional, Taniwaki, Shinichi, additional, Midorikawa, Ryuta, additional, Kojima, Satoki, additional, Muroya, Daisuke, additional, Arai, Shoichiro, additional, Shirahama, Takahisa, additional, Kanno, Hiroki, additional, Fukutomi, Shogo, additional, Goto, Yuichi, additional, Nomura, Yoriko, additional, Akashi, Masanori, additional, Sato, Toshihiro, additional, Sakai, Hisamune, additional, Hisaka, Toru, additional, and Akagi, Yoshito, additional

Published
2022
Full Text
View/download PDF

23. Cholangitis after Hemobilia: A Brief Overview

Author

Sou Hironobu, Sato Toshihiro, Arai Shoichiro, Akashi Masanori, Muroya Daisuke, Goto Yuichi, Sakai Hisamune, Taniwaki Satoshi, Nomura Yoriko, Okuda Koji, Imamura Tetsuo, Hisaka Toru, Okabe Yoshinobu, and Akagi Yoshito

Subjects
medicine.medical_specialty, medicine.anatomical_structure, Bile duct, business.industry, Biliary tract, Internal medicine, Hemostasis, medicine, Gallstones, Malignancy, medicine.disease, business, Gastroenterology
Abstract

Hemobilia, defined as the hemorrhage into the biliary tract and blood clots in the bile duct is an uncommon cause of severe cholangitis. The majority of hemobilia are caused by iatrogenic and trauma, gallstones, inflammation, vascular disorders, and malignancy. Hemobilia can cause recurrent obstructive cholangitis and it may bring a fatal patient's condition. The management of major hemobilia consists of hemostasis and reduction of biliary pressure to prevent or cure a cholangitis occurred in succession.

Published
2021

24. Preoperative Chemotherapy Followed by Hepatectomy for Potentially Resectable UICC7 Stage IIIA, IIIB Hepatocellular Carcinoma; A Phase II Clinical Trial

Author

GOTO, YUICHI, primary, NIIZEKI, TAKASHI, additional, FUKUTOMI, SHOGO, additional, SHIRONO, TOMOTAKE, additional, SHIMOSE, SHIGEO, additional, IWAMOTO, HIDEKI, additional, KOJIMA, SATOKI, additional, KANNO, HIROKI, additional, UCHINO, YOSHIHIRO, additional, SASAKI, SHIN, additional, SHIRAHAMA, NOBUHISA, additional, MUROYA, DAISUKE, additional, NOMURA, YORIKO, additional, AKASHI, MASANORI, additional, NAKAYAMA, GOICHI, additional, HIRAKAWA, YUSUKE, additional, SATO, TOSHIHIRO, additional, YOSHITOMI, MUNEHIRO, additional, SAKAI, HISAMUNE, additional, HISAKA, TORU, additional, KAKUMA, TATSUYUKI, additional, KOGA, HIRONORI, additional, TORIMURA, TAKUJI, additional, AKAGI, YOSHITO, additional, and OKUDA, KOJI, additional

Published
2021
Full Text
View/download PDF

25. Prognostic Factors for Distal Bile Duct Carcinoma After Surgery

Author

KAWAHARA, RYUICHI, primary, MIDORIKAWA, RYUUTA, additional, TANIWAKI, SHINICHI, additional, KOJIMA, SATOKI, additional, KANNO, HIROKI, additional, YOSHITOMI, MUNEHIRO, additional, NOMURA, YORIKO, additional, GOTO, YUICHI, additional, SATOU, TOSHIHIRO, additional, SAKAI, HISAMUNE, additional, ISHIKAWA, HIROTO, additional, HISAKA, TORU, additional, YASUNAGA, MASAFUMI, additional, SAKAUE, TAKAHIKO, additional, USHIJIMA, TOMOYUKI, additional, YASUMOTO, MAKIKO, additional, OKABE, YOSHINOBU, additional, TANIGAWA, MASAHIKO, additional, NAITOU, YOSHIKI, additional, YANO, HIROHISA, additional, and OKUDA, KOJI, additional

Published
2021
Full Text
View/download PDF

27. Hepatic Epithelioid Hemangioendothelioma Presenting Synchronously with Hepatocellular Carcinoma

Author

Kanno, Hiroki, primary, Sato, Toshihiro, additional, Midorikawa, Ryuta, additional, Kojima, Satoki, additional, Fukutomi, Shogo, additional, Goto, Yuichi, additional, Nomura, Yoriko, additional, Yoshitomi, Munehiro, additional, Kawahara, Ryuichi, additional, Sakai, Hisamune, additional, Hisaka, Toru, additional, Akagi, Yoshito, additional, and Okuda, Koji, additional

Published
2021
Full Text
View/download PDF

28. The Expression of PEDF and its Putative Receptors in Hepatocellular Carcinoma and Background Liver Tissue

Author

AKIBA, JUN, primary, YOSHIDA, TAKAFUMI, additional, SADASHIMA, EIJI, additional, MURATA, KAZUYA, additional, MATSUI, TAKANORI, additional, YAMAGISHI, SHO-ICHI, additional, KUSANO, HIRONORI, additional, MIHARA, YUTARO, additional, MIZUOCHI, SHINJI, additional, KINJOU, YOSHINAO, additional, NAITO, YOSHIKI, additional, HISAKA, TORU, additional, SAKAI, HISAMUNE, additional, OKUDA, KOJI, additional, NAKASHIMA, OSAMU, additional, and YANO, HIROHISA, additional

Published
2021
Full Text
View/download PDF

31. Quercetin Suppresses Proliferation of Liver Cancer Cell Lines In Vitro

Author

HISAKA, TORU, primary, SAKAI, HISAMUNE, additional, SATO, TOSHIHIRO, additional, GOTO, YUICHI, additional, NOMURA, YORIKO, additional, FUKUTOMI, SHOGO, additional, FUJITA, FUMIHIKO, additional, MIZOBE, TOMOAKI, additional, NAKASHIMA, OSAMU, additional, TANIGAWA, MASAHIKO, additional, NAITO, YOSHIKI, additional, AKIBA, JUN, additional, OGASAWARA, SACHIKO, additional, NAKASHIMA, KOUTA, additional, AKAGI, YOSHITO, additional, OKUDA, KOJI, additional, and YANO, HIROHISA, additional

Published
2020
Full Text
View/download PDF

34. Sinusoidal Obstruction Syndrome and Postoperative Complications Resulting from Preoperative Chemotherapy for Colorectal Cancer Liver Metastasis

Author

HISAKA, TORU, primary, ISHIKAWA, HIROTO, additional, SAKAI, HISAMUNE, additional, KAWAHARA, RYUICHI, additional, GOTO, YUICHI, additional, NOMURA, YORIKO, additional, YASUNAGA, MASAFUMI, additional, KINUGASA, TETSUSHI, additional, FUJITA, FUMIHIKO, additional, MIZOBE, TOMOAKI, additional, FUKAHORI, MASARU, additional, MIWA, KEISUKE, additional, NAKASHIMA, OSAMU, additional, TANIGAWA, MASAHIKO, additional, NAITO, YOSHIKI, additional, AKIBA, JUN, additional, YANO, HIROHISA, additional, TANAKA, HIROYUKI, additional, AKAGI, YOSHITO, additional, and OKUDA, KOJI, additional

Published
2019
Full Text
View/download PDF

35. Expression of Matrix Metalloproteinases in Intraductal Papillary Mucinous Neoplasm of the Pancreas

Author

AKASHI, MASANORI, primary, HISAKA, TORU, additional, SAKAI, HISAMUNE, additional, ISHIKAWA, HIROTO, additional, KAWAHARA, RYUICHI, additional, GOTO, YUICHI, additional, NOMURA, YORIKO, additional, YASUNAGA, MASAFUMI, additional, FUJITA, FUMIHIKO, additional, TANIGAWA, MASAHIKO, additional, NAITO, YOSHIKI, additional, AKIBA, JUN, additional, YANO, HIROHISA, additional, TANAKA, HIROYUKI, additional, AKAGI, YOSHITO, additional, and OKUDA, KOJI, additional

Published
2019
Full Text
View/download PDF

36. Clinicopathological Study of Resections of Intraductal Papillary Neoplasm of the Bile Duct

Author

SATO, TOSHIHIRO, primary, HISAKA, TORU, additional, SAKAI, HISAMUNE, additional, ISHIKAWA, HIROTO, additional, KAWAHARA, RYUICHI, additional, GOTO, YUICHI, additional, NOMURA, YORIKO, additional, YASUNAGA, MASAFUMI, additional, FUJITA, FUMIHIKO, additional, TANIGAWA, MASAHIKO, additional, NAITO, YOSHIKI, additional, AKIBA, JUN, additional, YANO, HIROHISA, additional, TANAKA, HIROYUKI, additional, AKAGI, YOSHITO, additional, and OKUDA, KOJI, additional

Published
2019
Full Text
View/download PDF

37. Clinical and Prognostic Significance of Neoplastic Spindle Cells in Gallbladder Cancer

Author

MIDORIKAWA, RYUTA, primary, HISAKA, TORU, additional, SAKAI, HISAMUNE, additional, NOMURA, YORIKO, additional, GOTO, YUICHI, additional, SATO, TOSHIHIRO, additional, KAWAHARA, RYUICHI, additional, ISHIKAWA, HIROTO, additional, FUJITA, FUMIHIKO, additional, YASUNAGA, MASAFUMI, additional, TANIGAWA, MASAHIKO, additional, NAITO, YOSHIKI, additional, AKIBA, JUN, additional, YANO, HIROHISA, additional, TANAKA, HIROYUKI, additional, AKAGI, YOSHITO, additional, and OKUDA, KOJI, additional

Published
2019
Full Text
View/download PDF

38. Evaluation of Surgical Procedures for T2 Gallbladder Cancer in Terms of Recurrence and Prognosis

Author

KAWAHARA, RYUICHI, primary, SHIRAHAMA, TAKAHISA, additional, ARAI, SHYOICHIROU, additional, MUROYA, DAISUKE, additional, NOMURA, YORIKO, additional, FUKUTOMI, SHOGO, additional, SHIRAHAMA, NOBUHISA, additional, TAKAGI, KATSUAKI, additional, GOTO, YUICHI, additional, AKASHI, MASANORI, additional, MARUYAMA, YUICHIROU, additional, SAKAI, HISAMUNE, additional, ISHIKAWA, HIROTO, additional, HISAKA, TORU, additional, YASUNAGA, MASAFUMI, additional, HORIUCHI, HIROYUKI, additional, OKUDA, KOJI, additional, AKAGI, YOSHITO, additional, and TANAKA, HIROYUKI, additional

Published
2016
Full Text
View/download PDF

39. A Case of Intra Abdominal Desmoid Tumor Preoperatively Diagnosed as a Pancreatic Tumor

Author

Sakai, Takenori, primary, Mikagi, Kazuhiro, additional, Akasu, Gen, additional, Ootuka, Takahiko, additional, Naruyama, Yuichiro, additional, Kawahara, Ryuiti, additional, Sakai, Hisamune, additional, Hisaka, Toru, additional, Uchida, Shinzi, additional, Horiuchi, Hironori, additional, Kinosita, Hisafumi, additional, Okabe, Yosinobu, additional, Naito, Yoshiki, additional, and Kusano, Hironori, additional

Published
2009
Full Text
View/download PDF

42. A case of intra abdominal desmoid tumor preoperatively diagnosed as a pancreatic tumor

Author

SAKAI, Takenori, primary, MIKAGI, Kazuhiro, additional, AKASU, Gen, additional, OOTUKA, Takahiko, additional, MARUYAMA, Yuichiro, additional, KAWAHARA, Ryuiti, additional, SAKAI, Hisamune, additional, HISAKA, Toru, additional, UCHIDA, Shinzi, additional, HORIUCHI, Hironori, additional, KINOSITA, Hisafumi, additional, OKABE, Yosinobu, additional, NAITO, Yoshiki, additional, and KUSANO, Hironori, additional

Published
2008
Full Text
View/download PDF

43. Evaluation of Resection of the Papilla of Vater for the Treatment of Cancer in the Papilla of Vater

Author

KINOSHITA, HISAFUMI, primary, HARA, MASAO, additional, NISHIMURA, KAZUNORI, additional, KODAMA, TAKAHITO, additional, MATSUO, HIDEKI, additional, KAWAHARA, RYUICHI, additional, YASUNAGA, MASAFUMI, additional, SAKAI, HISAMUNE, additional, ODO, MASAHARU, additional, OKUDA, KOJI, additional, SHIROUZU, KAZUO, additional, and AOYAGI, SHIGEAKI, additional

Published
2003
Full Text
View/download PDF

44. Intrabiliary growth type of metastasis from colon cancer, 12 years after curative colectomy: a case report.

Author

Nomura, Yoriko, Fukutomi, Shogo, Shirahama, Nobuhisa, Sakai, Hisamune, Hisaka, Toru, Akagi, Yoshito, Tanaka, Hiroyuki, Okuda, Koji, Sasaki, Shin, Kusano, Hironori, Yano, Hirohisa, Akiba, Jun, and Nakashima, Osamu

Subjects
COLON cancer, METASTASIS, CARCINOEMBRYONIC antigen, COMPUTED tomography, IMMUNOSTAINING, BILE ducts, COLECTOMY, COLON tumors, BILE duct tumors, LIVER tumors, CHOLANGIOCARCINOMA, DIAGNOSIS
Abstract

Background: Liver is a common location of colorectal metastasis, but intrabiliary growth of liver metastasis is not well recognized. Furthermore, intrabiliary metastasis that discovered over 10 years after excision has rarely been described.Case Presentation: An 80-year-old man was admitted due to the presence of a liver mass in segment 5 (S5) concomitant with elevated carcinoembryonic antigen (CEA), and carbohydrate antigen (CA) 19-9. He underwent right hemicolectomy for colon cancer 12 years prior. Enhanced computed tomography (CT) showed dilated bile ducts with periductal enhancement in S5; hence, cholangiocarcinoma was suspected. Upon anterior segmentectomy, we observed that the cut surface of the specimen exhibited a yellowish-white tumor within the bile ducts. Histologically, the tumor formed within the papillary process, extended along the lumen, and replaced the normal bile duct epithelium. Immunohistochemical studies showed that the liver tumor and primary colon cancer were negative for cytokeratin (CK) 7 and positive for CK20 and Caudal-type homeobox transcription factor 2 (CDX-2). In addition, both tumors showed a same KRAS mutation. We diagnosed the liver tumor as liver metastasis recurrence from colon cancer.Conclusion: Intrabiliary growth type of metastasis (IGM) is difficult to distinguish from cholangiocarcinoma, and sometimes develops long after surgery; thus, careful examination of a patient's history is needed in such cases. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

45. A Multidisciplinary Therapeutic Approach Proposal for Huge Hepatocellular Carcinomas Exceeding 10 cm in Diameter.

Author

Goto Y, Niizeki T, Sakai H, Akashi M, Fukutomi S, Hashimoto K, Iwamoto H, Shimose S, Shirono T, Yoshida T, Isobe T, Mori N, Kawaguchi T, Ishibashi N, Fujita F, and Hisaka T

Subjects
Humans, Male, Female, Middle Aged, Aged, Combined Modality Therapy, Adult, Infusions, Intra-Arterial, Retrospective Studies, Aged, 80 and over, Treatment Outcome, Survival Rate, Carcinoma, Hepatocellular pathology, Carcinoma, Hepatocellular surgery, Carcinoma, Hepatocellular therapy, Carcinoma, Hepatocellular mortality, Liver Neoplasms pathology, Liver Neoplasms surgery, Liver Neoplasms therapy, Liver Neoplasms mortality, Hepatectomy
Abstract

Background/aim: The outcome of hepatectomy for a hepatocellular carcinoma (HCC) exceeding 10 cm (i.e., huge HCC) remains unfavorable. The aim of the current study was to evaluate the optimal therapeutic approach for huge HCCs., Patients and Methods: Between 2008 and 2018, patients with a huge HCC who underwent treatment at our institution were enrolled. Cases not meeting the criteria (Child-Pugh grade A or performance status 0/1) and patients with distant metastases were excluded. Patients were stratified into three groups: a) upfront hepatectomy (Upfront); b) hepatectomy subsequent to hepatic arterial infusion chemotherapy (HAIC-Hr); and c) HAIC alone (HAIC). Survival rates, including overall survival (OS) and progression-free survival (PFS), were analyzed. The cancer-specific mortality attributed to recurrence within one year after surgery was defined as "futile surgery"; the rate of futile surgery was also assessed., Results: A total of 70 cases were censored (Upfront/HAIC-Hr/HAIC: 28/13/29). The 5-year PFS and OS rates for Upfront, HAIC-Hr, and HAIC were 7.7%, 69.2%, and 6.9%, and 37.1%, 79.1%, and 19.7%, respectively. The number of futile surgeries was 6 (21.4%) in the Upfront group, whereas no such cases occurred in the HAIC-Hr group., Conclusion: Although hepatectomy was advocated in the Upfront group due to the potential resectability, the outcomes were comparable to those of the HAIC group. Conversely, the HAIC-Hr group had promising outcomes, marked by a decreased prevalence of futile surgeries. Huge HCCs should be regarded as borderline resectable, even when deemed potentially resectable. Therefore, a multidisciplinary therapeutic approach might be reasonable., (Copyright © 2024 International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.)

Published
2024
Full Text
View/download PDF

46. Hemoglobin, Albumin, Lymphocyte, and Platelet (HALP) Score As a Predictor of Prognosis After Hepatectomy.

Author

Hashimoto K, Kanno H, Sakai H, Miyazaki D, Fukutomi S, Arai S, Goto Y, Akashi M, Isobe T, Mori N, Ishibashi N, Fujita F, and Hisaka T

Subjects
Adult, Aged, Female, Humans, Male, Middle Aged, Blood Platelets pathology, Blood Platelets metabolism, Lymphocytes, Prognosis, Retrospective Studies, Serum Albumin analysis, Serum Albumin metabolism, Aged, 80 and over, Carcinoma, Hepatocellular surgery, Carcinoma, Hepatocellular mortality, Carcinoma, Hepatocellular blood, Carcinoma, Hepatocellular pathology, Hemoglobins analysis, Hemoglobins metabolism, Hepatectomy mortality, Liver Neoplasms surgery, Liver Neoplasms mortality, Liver Neoplasms blood, Liver Neoplasms pathology
Abstract

Background/aim: The hemoglobin, albumin, lymphocyte, and platelet (HALP) score is an immune-nutritional assessment score that is a prognostic indicator for several malignant tumors. This study aimed to investigate its prognostic value in patients who underwent hepatectomy for hepatocellular carcinoma., Patients and Methods: Data of 685 patients with hepatocellular carcinoma who underwent hepatectomy at Kurume University between 2006 and 2021 were retrospectively analyzed. The patients were classified into high and low HALP score groups based on a cut-off HALP score determined using a receiver operating characteristic curve. To minimize bias, 1:1 propensity score matching was performed. Kaplan-Meier curves were used to estimate survival time, and data were evaluated using the log-rank test. Univariate and multivariate analyses were performed using Cox hazard or logistic regression models for assessing survival time and postoperative outcomes, respectively., Results: Low HALP scores were significantly associated with poor overall survival (p=0.0066). Univariate and multivariate analyses revealed that the HALP score independently predicted overall survival (p=0.005). However, the HALP score was not significantly related to recurrence-free survival or postoperative outcomes., Conclusion: The HALP score is a simple inexpensive tool for predicting prognosis after hepatectomy for hepatocellular carcinoma., (Copyright © 2024 International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.)

Published
2024
Full Text
View/download PDF

47. Safety and Feasibility of Laparoscopic Anatomical Liver Resection for Hepatocellular Carcinoma: A Propensity Score-matched Study.

Author

Sakai H, Goto Y, Fukutomi S, Arai S, Midorikawa R, Hashimoto K, Miyazaki D, Akashi M, Ishibashi N, Okuda K, Fujita F, and Hisaka T

Subjects
Humans, Male, Female, Middle Aged, Retrospective Studies, Aged, Treatment Outcome, Postoperative Complications epidemiology, Postoperative Complications etiology, Length of Stay, Adult, Operative Time, Carcinoma, Hepatocellular surgery, Carcinoma, Hepatocellular pathology, Carcinoma, Hepatocellular mortality, Liver Neoplasms surgery, Liver Neoplasms pathology, Liver Neoplasms mortality, Laparoscopy methods, Laparoscopy adverse effects, Propensity Score, Hepatectomy methods, Hepatectomy adverse effects, Feasibility Studies
Abstract

Background/aim: Laparoscopic anatomical liver resection (LAR) for hepatocellular carcinoma (HCC) is technically demanding. Therefore, this study aimed to compare the perioperative and long-term oncological outcomes of LAR and open anatomical liver resection (OAR) for HCC., Patients and Methods: We retrospectively analyzed 460 consecutive patients who underwent anatomical liver resection as the initial treatment for primary HCC between January 2010 and February 2024. Patients were categorized into the LAR and OAR groups, and surgical outcomes between the groups were compared using 1:1 propensity score matching (PSM)., Results: After PSM, the LAR and OAR groups included 100 patients each. The LAR group exhibited significantly less blood loss (80 vs. 436 ml; p<0.0001), lower transfusion rates (0% vs. 12%; p=0.0002), shorter operative time (345 vs. 398 min; p=0.0009), lower postoperative morbidity rates (6% vs. 34%; p<0.0001), and shorter postoperative hospital stay (8 vs. 15 days; p<0.0001) than the OAR group. The 1-, 3-, and 5-year overall survival rates were 97.7%, 96.2%, and 89.7%, respectively, in the LAR group and 98.0%, 92.7%, and 88.4%, respectively, in the OAR group (p=0.5874). The 1-, 3-, and 5-year recurrence-free survival rates were 93.2%, 75.7%, and 60.7%, respectively, in the LAR group and 86.0%, 64.5%, and 59.1%, respectively, in the OAR group (p=0.2314)., Conclusion: LAR showed improvements in perioperative complications, reduced postoperative hospital stay, and comparable recurrence-free and overall survival rates with those of OAR. Therefore, LAR for HCC is considered safe, feasible, and oncologically acceptable in selected patients., (Copyright © 2024 International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.)

Published
2024
Full Text
View/download PDF

48. Clinicopathological Study of Resected and Recurrent Cases of Intrahepatic Intraductal Papillary Neoplasm of the Bile Duct.

Author

Arai S, Sakai H, Akashi M, Goto Y, Miyazaki D, Hashimoto K, Midorikawa R, Fukutomi S, Yoshida T, Isobe T, Mori N, Ishibashi N, Naito Y, Akiba J, Fujita F, and Hisaka T

Subjects
Humans, Male, Female, Aged, Middle Aged, Bile Ducts, Intrahepatic pathology, Bile Ducts, Intrahepatic surgery, Carcinoma, Papillary surgery, Carcinoma, Papillary pathology, Aged, 80 and over, Postoperative Complications, Prognosis, Bile Duct Neoplasms surgery, Bile Duct Neoplasms pathology, Neoplasm Recurrence, Local pathology, Neoplasm Recurrence, Local surgery, Hepatectomy methods, Pancreaticoduodenectomy
Abstract

Background/aim: This study aimed to characterize intraductal papillary neoplasm of the bile duct (IPNB) in patients undergoing initial and recurrent surgical resection and to evaluate the appropriateness of surgical treatment strategies., Patients and Methods: This study included 14 patients who underwent liver resection for intrahepatic IPNB. We assessed intraoperative and postoperative clinicopathological factors in patients undergoing both initial and recurrent surgeries., Results: Four patients experienced recurrence after initial surgery; all underwent pancreaticoduodenectomy. Postoperative complications were classified as Clavien-Dindo Grade 1-2 in three patients and Grade IIIb in one patient. There were no in-hospital deaths., Conclusion: Pancreaticoduodenectomy for recurrent cases following hepatectomy for IPNB is considered safe within an acceptable range and contributes to a favorable long-term prognosis., (Copyright © 2024 International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.)

Published
2024
Full Text
View/download PDF

49. [Minimally Invasive Conversion Hepatectomy for Advanced Hepatocellular Carcinoma].

Author

Sakai H, Goto Y, Shimose S, Niizeki T, Kawaguchi T, Akiba J, Yano H, Akagi Y, Fujita F, and Hisaka T

Subjects
Humans, Hepatectomy, Infusions, Intra-Arterial, Bevacizumab therapeutic use, Carcinoma, Hepatocellular drug therapy, Carcinoma, Hepatocellular surgery, Carcinoma, Hepatocellular pathology, Liver Neoplasms drug therapy, Liver Neoplasms surgery, Liver Neoplasms pathology
Abstract

Some cases of advanced hepatocellular carcinoma(HCC)diagnosed as unresectable(UR)have been reported to undergo conversion surgery following systemic therapy. Furthermore, the combination of atezolizumab plus bevacizumab(Atez/Bev) shows potential therapeutic effects in conversion surgery for UR-HCC. At our hospital, neoadjuvant chemotherapy(NAC) using New-FP therapy(hepatic arterial infusion chemotherapy: HAIC)has been performed for borderline resectable HCC. New-FP therapy for advanced HCC with macrovascular invasion has a high response rate of 70%. For hepatectomy after NAC, a high response rate is required as a pretreatment, and New-FP therapy may be useful as the initial treatment. Limited reports exist of the laparoscopic approach in conversion surgery for advanced HCC. However, 14 cases of minimally invasive liver resection, including 10 cases after New-FP therapy and 4 cases after Atez/Bev therapy, have been safely performed conversion surgery for advanced HCC. In selected patients with advanced HCC, minimally invasive liver resection may be safely performed if the tumor shows shrinkage with various treatments.

Published
2023

50. [A Case of the Spontaneously Ruptured Recurrence Hepatic Angiosarcoma after Hepatic Resection].

Author

Arai S, Miyazaki D, Hashimoto K, Midorikawa R, Fukutomi S, Muroya D, Akashi M, Goto Y, Sakai H, Fujita F, and Hisaka T

Subjects
Male, Humans, Aged, Neoplasm Recurrence, Local, Rupture, Hemangiosarcoma surgery, Liver Neoplasms therapy, Embolization, Therapeutic, Carcinoma, Hepatocellular surgery
Abstract

A 67-year-old male was referred to our hospital in a state of shock. Transcatheter arterial embolization(TAE)was performed for the diagnosis of liver tumor rupture, followed by extended posterior area resection 18 days later. Histopathologically, he was diagnosed with hepatic angiosarcoma. The patient was discharged 18 days after the surgery, but readmitted on the 51st day due to bleeding shock caused by the rupture of a recurrent tumor in the liver. Although TAE was performed, the patient developed hepatic failure and died on postoperative day 81. Autopsy revealed multiple intrahepatic recurrence and peritoneal dissemination. Herein, we report a case of ruptured hepatic angiosarcoma that underwent hepatic resection after TAE and had a rapid outcome due to early postoperative rupture of recurrent lesion.

Published
2023

Catalog

Books, media, physical & digital resources
See catalog results